The estimated Net Worth of Ran Frenkel is at least $6.9 Millón dollars as of 28 February 2022. Mr. Frenkel owns over 1,663 units of Karyopharm Therapeutics Inc stock worth over $124,535 and over the last 10 years he sold KPTI stock worth over $292,548. In addition, he makes $6,481,860 as Chief Development Operations Officer at Karyopharm Therapeutics Inc.
Sign up
Mr. Frenkel KPTI stock SEC Form 4 insiders trading
Ran has made over 12 trades of the Karyopharm Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 1,663 units of KPTI stock worth $17,029 on 28 February 2022.
The largest trade he's ever made was exercising 9,675 units of Karyopharm Therapeutics Inc stock on 11 February 2021 worth over $7,160. On average, Ran trades about 2,304 units every 115 days since 2014. As of 28 February 2022 he still owns at least 168,290 units of Karyopharm Therapeutics Inc stock.
You can see the complete history of Mr. Frenkel stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ran Frenkel biography
Ran Frenkel serves as Chief Development Operations Officer of the Company. Mr. Frenkel was appointed Executive Vice President, Worldwide Development Operations of Karyopharm in October 2014 and was appointed Chief Development Operations Officer in January 2015. Prior to joining Karyopharm, Mr. Frenkel held a number of senior management roles in Europe, Israel and the United States, most recently as Managing Director EMEA from January 2013 to October 2014 for Clinipace Worldwide, an international clinical research organization, where he had responsibility for the overall management of the organization in Europe, the Middle East and Africa. Prior to becoming Managing Director EMEA, Mr. Frenkel was VP International Business Development at Clinipace Worldwide from July 2011 to January 2013. Prior to joining Clinipace Worldwide, from January 2007 to August 2011, Mr. Frenkel established and managed the Israeli office of PFC Pharma Focus AG, which was acquired by Clinipace Worldwide in 2011, and from 2004 to 2007, he held the position of Managing Director at Actelion Pharmaceuticals with responsibility for all science and business affairs of the company in Israel. Mr. Frenkel received a BPharm from Hebrew University.
What is the salary of Ran Frenkel?
As the Chief Development Operations Officer of Karyopharm Therapeutics Inc, the total compensation of Ran Frenkel at Karyopharm Therapeutics Inc is $6,481,860. There are no executives at Karyopharm Therapeutics Inc getting paid more.
How old is Ran Frenkel?
Ran Frenkel is 51, he's been the Chief Development Operations Officer of Karyopharm Therapeutics Inc since 2015. There are 14 older and 7 younger executives at Karyopharm Therapeutics Inc. The oldest executive at Karyopharm Therapeutics Inc is Garen Bohlin, 72, who is the Independent Director.
What's Ran Frenkel's mailing address?
Ran's mailing address filed with the SEC is C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON, MA, 02459.
Insiders trading at Karyopharm Therapeutics Inc
Over the last 11 years, insiders at Karyopharm Therapeutics Inc have traded over $149,223,596 worth of Karyopharm Therapeutics Inc stock and bought 562,763 units worth $10,312,371 . The most active insiders traders include Deepika Pakianathan, Ltd Czernik Marcin Hadjimic... y Mikael Dolsten. On average, Karyopharm Therapeutics Inc executives and independent directors trade stock every 12 days with the average trade being worth of $26,350. The most recent stock trade was executed by Michael Mano on 4 September 2024, trading 3,971 units of KPTI stock currently worth $2,859.
What does Karyopharm Therapeutics Inc do?
karyopharm therapeutics inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. for more information, please visit www.karyopharm.com
What does Karyopharm Therapeutics Inc's logo look like?
Complete history of Mr. Frenkel stock trades at Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc executives and stock owners
Karyopharm Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Ran Frenkel,
Chief Development Operations Officer -
Michael Kauffman,
Co-Founder, Chief Executive Officer and Director -
Sharon Shacham,
President, Chief Scientific Officer -
Christopher Primiano,
Executive Vice President, Chief Business Officer, General Counsel and Secretary -
Dr. Michael G. Kauffman M.D., Ph.D.,
Co-Founder, Sr. Clinical Advisor & Director -
Dr. Michael G. Kauffman,
Co-Founder, Sr. Clinical Advisor & Director -
Dr. Sharon Shacham M.B.A., Ph.D.,
Co-Founder & Chairman of Scientific Advisory Board -
Dr. Sharon Shacham,
Co-Founder, Chief Scientific Officer & Chairman of Scientific Advisory Board -
Michael P. Mason CPA, M.B.A.,
Sr. VP, CFO & Treasurer -
Mansoor Mirza,
Director and Clinical Advisor -
Barry Greene,
Lead Independent Director -
Deepa Pakianathan,
Independent Director -
Garen Bohlin,
Independent Director -
Dr. Mansoor Raza Mirza M.D.,
Clinical Consultant, Member of Scientific Advisory Board & Independent Director -
Mikael Dolsten,
Independent Director -
Dr. Mansoor Raza Mirza,
Clinical Consultant, Member of Scientific Advisory Board & Director -
Richard A. Paulson M.B.A.,
Pres, CEO & Director -
Richard Paulson,
Independent Director -
Christy Oliger,
Director -
Perry Monaco,
Senior Vice President of Sales -
Jatin Shah,
Executive Vice President, Chief Medical Officer -
Tanya Lewis,
Executive Vice President, Chief Regulatory Officer and Quality Officer -
Michael Mason,
Chief Financial Officer, Senior Vice President, Treasurer -
James Accumanno J.D.,
Chief Compliance Officer -
Elhan Webb C.F.A.,
Sr. VP of Investor Relations -
Lisa Meletta J.D.,
VP of Legal & Chief Compliance Officer -
Michael J. Mano J.D.,
Sr. VP, Gen. Counsel & Sec. -
Pierre S. Sayad M.S., Ph.D.,
VP of Global Medical & Scientific Affairs -
Cameron Peters,
VP of Fin., Assistant Treasurer & Principal Accounting Officer -
Ran Frenkel R.Ph., RPh,
Exec. VP & Chief Devel. Officer -
Zhen Su,
-
Carsten Thiel,
Director -
Kenneth E Weg,
Director -
J. Scott Garland,
Director -
Justin A Renz,
EVP, CFO & Treasurer -
Michael Falvey,
EVP, CFO & Treasurer -
Peter Honig,
Director -
Anand Varadan,
EVP, Chief Commercial Officer -
Cameron Peters,
VP of Finance -
Marcin Hadjimichael Andreas...,
-
Paul Brannelly,
SVP, FIN & ADMIN, SEC & TRES -
Ltd Czernik Marcin Hadjimic...,
-
Ltd Czernik Marcin Hadjimic...,
-
John Demaree,
Chief Commercial Officer -
Deepika Pakianathan,
-
Chen Schor,
-
Stephen Mitchener,
SVP, Chief Business Officer -
Michael Mano,
SVP, General Counsel&Secretary -
Sohanya Roshan Cheng,
EVP & Chief Commercial Officer -
Stuart Poulton,
EVP, Chief Development Officer -
Reshma Rangwala,
EVP & Chief Medical Officer